This is a condition where new, abnormal blood vessels grow in the choroid layer of the eye. These vessels can leak fluid or blood, potentially leading to vision loss.
Every report comes from a Lived member, sent anonymously.
Have you tried Eylea (Aflibercept) for Choroidal Neovascularization?
Choroidal neovascularization (CNV) is the growth of abnormal new blood vessels from the choroid, the layer of blood vessels that nourishes the back of the eye, into the space beneath the retina. These fragile vessels tend to leak fluid and blood under the macula, the small central area of the retina responsible for sharp, detailed vision. The result can be fast damage to the vision you use for reading, recognizing faces and driving. CNV is not a disease on its own so much as a complication of other eye conditions. It is the process behind wet (neovascular) age-related macular degeneration (AMD), which is its most common cause, and it accounts for most severe vision loss from AMD. Typical early signs are straight lines that look wavy or bent, a blurry or dark patch near the center of vision, or a sudden drop in clarity in one eye. Side vision is usually spared, and the condition is not painful, so a change can go unnoticed if the other eye is compensating.
CNV develops when the layers under the retina are damaged or under stress, and the eye responds by producing a signaling protein called VEGF (vascular endothelial growth factor) that drives new vessel growth in the wrong place. Age-related macular degeneration is by far the most common setting, so the main risk factors for AMD apply: being over 55, a family history of AMD, smoking and being white. Someone who already has wet AMD in one eye has a higher chance of developing it in the other. In younger adults, CNV most often occurs with pathologic myopia, a severe form of nearsightedness in which the eye is elongated and the tissues at the back are stretched thin. Inflammation inside the eye (uveitis), whether from infection or an autoimmune cause, is another important cause. Less common causes include presumed ocular histoplasmosis (scarring from a fungal infection) and angioid streaks, breaks in a supporting layer of the retina that can occur with some inherited connective tissue and blood disorders. Sometimes no clear cause is found.
An eye specialist, usually an ophthalmologist or retina specialist, checks central vision and examines the retina after dilating the pupils with eye drops. The key test is optical coherence tomography (OCT), a quick, painless scan that produces cross-section images of the retina and shows fluid, blood or thickening under the macula. To see the abnormal vessels themselves, the specialist may use angiography. Fluorescein angiography involves injecting a dye into an arm vein and photographing it as it passes through the eye's vessels; leaking vessels light up. OCT angiography is a newer, dye-free scan that maps blood flow. Identifying the underlying cause, such as AMD, high myopia or inflammation, matters because it shapes treatment and follow-up. The same scans are repeated at later visits to judge whether the vessels are still active.
Treatment aims to stop the abnormal vessels from leaking and bleeding so that the macula is protected. It can slow or halt vision loss, and some people regain some sight, but it does not reliably restore vision that has already been lost to scarring. Starting promptly gives the best chance of keeping useful vision. The main treatment is anti-VEGF medicine, which blocks the signal that drives the vessel growth. It is given as an injection into the eye in a clinic: the eye is numbed and cleaned, and the medicine is delivered through a very fine needle. Options include ranibizumab (Lucentis), aflibercept (Eylea) and faricimab (Vabysmo), which also blocks a second growth signal called angiopoietin-2. Bevacizumab, a related medicine, works about as well as ranibizumab for wet AMD and costs much less. Not every product is approved for every cause; for example, ranibizumab is approved in the US for CNV from pathologic myopia, while aflibercept and faricimab are approved for wet AMD. The effect of each injection wears off, so treatment is repeated. Most people start with monthly injections, and the specialist then adjusts the interval based on scans. People with myopic CNV often need fewer injections than people with wet AMD. Raised eye pressure and, rarely, infection inside the eye are the main injection risks; serious infection occurred in under 1% of treated people in trials. Photodynamic therapy (PDT) is used less often, sometimes alongside injections. A light-sensitive drug, verteporfin (Visudyne), is given into an arm vein and then activated by a low-energy laser aimed at the abnormal vessels. Because the drug makes skin and eyes sensitive to light, people need to avoid direct sunlight and bright indoor light for 5 days afterward. When CNV is caused by inflammation, controlling the underlying uveitis is also part of treatment.
For most people, CNV becomes a long-term condition that needs ongoing monitoring rather than a single fix. Injections are often needed for years, especially with wet AMD, and regular visits for scans set the schedule. Keeping to that schedule matters: the trial results that support these medicines came from regular dosing, and undertreatment is common in everyday care. Outcomes vary with the cause, how much damage occurred before treatment and how the eye responds. Some people keep most of their central vision, while others are left with a permanent blurred or blank area. In myopic CNV, treatment improves vision, but many eyes later develop thinning of the macula that limits long-term sight. Because CNV can affect the second eye, especially in AMD, checking each eye separately at home with an Amsler grid (a printed square of lines with a central dot) helps catch new distortion early. If central vision is reduced, low-vision services, magnifiers, better lighting and vision rehabilitation can help people stay independent with reading, cooking and other daily tasks.
See an eye doctor soon if your central vision has become blurry, dim or harder to use for reading, especially if you have AMD, a family history of it or severe nearsightedness. Contact your eye specialist right away, the same day if possible, if straight lines start to look wavy or crooked, or a new blurry, dark or blank spot appears in the center of your vision in either eye; this can mean CNV has started or become active again. In the days after an eye injection, a red, painful or light-sensitive eye, or worsening vision, needs immediate care from an ophthalmologist because it can signal an infection inside the eye.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Choroidal Neovascularization is like, what's helped you, or ask the community a question.